Evidence map›Paper›PMID 26465293›Full record

ArticlePloS one2015

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.

Daniel D Murray, Kazuo Suzuki, Matthew Law, Jonel Trebicka, Jacquie Neuhaus, Deborah Wentworth, Margaret Johnson, Michael J Vjecha, Anthony D Kelleher, Sean Emery and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
343.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2,740 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Daniel D MurrayThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
Kazuo SuzukiThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
Matthew LawThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
Jonel TrebickaDepartment of Internal Medicine, University of Bonn, Bonn, Germany.
Jacquie NeuhausUniversity of Minnesota, Minneapolis, Minnesota, United States of America.
Deborah WentworthUniversity of Minnesota, Minneapolis, Minnesota, United States of America.
Margaret JohnsonIan Charleson Day Centre, Royal Free Hampstead NHS Trust, London, United Kingdom.
Michael J VjechaInstitute for Clinical Research, Veterans Affairs Medical Center, Washington D.C., United States of America.
Anthony D KelleherThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
Sean EmeryThe Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
INSIGHT ESPRIT and SMART Study Groups
UNSW Sydney · AUUniversity of Minnesota · USRoyal Free London NHS Foundation Trust · GBUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. MATERIALS AND

methodsA set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed.

resultsNone of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR-145 correlated with nadir CD4+ T cell count. DISCUSSION: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection.

Indexed as

Antiretroviral Therapy, Highly ActiveGenetic Association StudiesAdultAnti-HIV AgentsBiomarkersCD4-Positive T-LymphocytesFemaleHIV-1HIV InfectionsHumansMaleMicroRNAsMiddle AgedAnti-HIV AgentsBiomarkersMicroRNAs

Identifiers

PMID26465293
PMCPMC4605674
OpenAlexW2338289743

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.